Biontech Se Stock Beta
| 22UA Stock | EUR 113.80 1.30 1.16% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech |
BioNTech SE Company Beta Analysis
BioNTech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current BioNTech Beta | 0.2 |
Most of BioNTech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, BioNTech SE has a Beta of 0.1973. This is 77.06% lower than that of the Healthcare sector and 85.81% lower than that of the Biotechnology industry. The beta for all Germany stocks is notably lower than that of the firm.
BioNTech Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in beta category among its peers.
As returns on the market increase, BioNTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNTech is expected to be smaller as well.
BioNTech Fundamentals
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Shares Owned By Insiders | 64.00 % | |||
| Shares Owned By Institutions | 18.41 % | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X | |||
| Price To Sales | 2.19 X | |||
| Revenue | 18.98 B | |||
| Gross Profit | 16.07 B | |||
| EBITDA | 15.13 B | |||
| Net Income | 10.29 B | |||
| Cash And Equivalents | 914.9 M | |||
| Cash Per Share | 3.75 X | |||
| Total Debt | 171.6 M | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 2.67 X | |||
| Book Value Per Share | 76.45 X | |||
| Cash Flow From Operations | 889.7 M | |||
| Earnings Per Share | 38.32 X | |||
| Price To Earnings To Growth | 0.04 X | |||
| Target Price | 334.89 | |||
| Number Of Employees | 4 K | |||
| Beta | 0.2 | |||
| Market Capitalization | 30.49 B | |||
| Total Asset | 15.83 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 15.83 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..